Clinical Trials Browser

Interventional × Axitinib × Clear all

NCT03595124 2026-05-27

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Phase 2 Active not recruiting

15 enrolled 15 charts

Carcinoma, Renal Cell

NCT03172754 2026-05-22

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell

NCT07227415 2026-05-22

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Phase 1/2 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT01334073 2026-05-14

EVAX

Phase 1 Completed

Carcinoma, Renal Cell

NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT02535533 2026-05-06

SLM + Axitinib for Clear Cell RCC

Phase 1/2 Completed

45 enrolled 18 charts

Kidney Neoplasms

NCT05327686 2026-05-04

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Phase 2/3 Completed

256 enrolled 25 charts

Neuroendocrine Tumors

NCT04355156 2026-04-16

AXMUS-C

Phase 2 Completed

52 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT05969496 2026-04-13

NEOPAX

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05808608 2026-04-07

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell

NCT07500831 2026-03-30

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

Phase NA Not yet recruiting

Carcinoma, Renal Cell

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT07123090 2026-03-25

SPARCC

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Phase 1 Recruiting

Neoplasm Metastasis

NCT07469683 2026-03-13

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Neoplasms

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

Carcinoma, Renal Cell

NCT01409200 2026-03-03

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Phase 2 Completed

Lymphatic Metastasis

NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 3 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1/2 Terminated

34 enrolled 44 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03092856 2025-12-17

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT05363631 2025-12-10

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Phase 1/2 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

Phase 2 Terminated

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Phase 2 Recruiting

Kidney Neoplasms

NCT03438708 2025-10-02

PADRES

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT07172386 2025-09-16

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT04258956 2025-09-11

AXAGIST

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07159191 2025-09-08

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Phase 2 Not yet recruiting

Advanced Renal Cell Carcinoma (aRCC)

NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT05949632 2025-08-03

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2 Active not recruiting

106 enrolled 16 charts

Endometrial Neoplasms

NCT03826589 2025-06-11

ALARICE

Phase NA Completed

Uterine Cervical Neoplasms

NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Phase 1/2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02597322 2025-04-06

AXIPAN

Phase 2 Completed

cT2a N0NxM0 Renal Tumor

NCT06889649 2025-03-21

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Phase 2 Recruiting

Radiation Therapy

NCT05256472 2025-03-06

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

Phase 2 Completed

Recurrence

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

Neoplasms